secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001140361-26-012891
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance
-------------------------------------------------------------------------

- Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.
- GAAP net loss $8.1M (-$0.19/shr); adjusted EBITDA $1.8M vs $1.3M prior year.
- Raised FY2026 net sales guidance to $313.5-315.5M; adjusted EBITDA now $10-12M (prev $8-10M).
- Tariff impact $1.3M in Q3; full-year tariff expectation unchanged at $4-6M.
- Cash $37.8M, debt-free; expects Q4 cash flow slightly negative due to $3-5M inventory build for sterilization shutdowns.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/0001140361-26-012891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/ef20069681_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-012891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer